glp 1 teeth The Weird Way GLP-1s Affect Your Ozempic Teeth: How GLP-1 Medications

In 2025, Novo Nordisks semaglutide awaits several first-time FDA decisions: Injectable GLP-1s 2025 Ozempic for T2DM and peripheral artery disease (PAD) 2H 2025 Wegovy for heart failure with preserved ejection fraction (HFpEF) and obesity Oral GLP-1s October 2025 new indication for oral Rybelsus for secondary CV risk reduction 4Q 2025 the first oral GLP-1 ( oral formulation of Wegovy 25 mg ) for weight loss and weight loss plus secondary CV risk reduction Given the considerable continued growth expected in the GLP-1 pipeline, Prime Therapeutics (Prime) talented team of clinical experts actively monitors this emerging landscape

Accordingly, the participant was included in the safety analysis set but excluded from the efficacy and PK analysis sets

Isabel, U.-V., de la Riera M

9 Durand, R., C.R